India to increase the drug inspection staff by 10 times
India’s drug regulator plans to increase its workforce especially because of the growing clinical trials.
Hyderabad, June 28, 2013: India's national regulatory body for pharmaceuticals and medical devices Central Drugs Standard Control Organization (CDSCO) plans to increase its drug inspection workforce by 10 times to effectively regulate the sector, especially because of the rising clinical trials in the country.
It may be noted here that CDSCO is considered the Indian counterpart of Food and Drug Administration (FDA) of United States and functions under India's union health ministry. CDSCO currently has staff strength of 200 plus in its drug and clinical trials inspection.
The regulator is also planning to set up eight more central laboratories and strengthen the state level regulatory agencies keeping in mind the growing clinical trials across the country. It may be noted here that an amount of Rs 1,200 crore has been earmarked towards setting up laboratories and staff costs.
The increase in the workforce and setting up of laboratories can be expected to further strengthen the stringent regulatory environment in the Indian pharma sector.